Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04009343 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 2025 to Dec 2026v9
  2. Study completion date: Mar 2025 to Dec 2025v8
  3. Study completion date: Jul 2024 to Mar 2025v7
  4. Study completion date: Nov 2023 to Jul 2024v6
  5. Study completion date: Nov 2022 to Nov 2023v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date changed from estimate of Sep 2020 to Aug 24, 2020
    • Study completion date: Apr 2021 to Nov 2022
    v4
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: May 2020 to Sep 2020
    • Site details revised
    v3
  3. Secondary endpoints: details revised at 2 of 5 entries
    • Study description expanded, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single-center phase II/III clinical investigation of the pharmacokinetics and pharmacodynamics of artemether-lumefantrine and dihydroartemisinin-piperaquine for gametocyte clearance and post-treatment chemoprotection in Zambian children with uncomplicated falciparum malaria.
Trial Details
NCT Number NCT04009343
Lead Sponsor Johns Hopkins Bloomberg School of Public Health
Collaborators: Tropical Diseases Research Centre
Conditions
(from sponsor)		 Uncomplicated Falciparum Malaria
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov